- Home
- SLI vs XNCR Comparison
SLI vs XNCR Comparison
Compare SLI & XNCR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SLI | XNCR |
|---|---|---|
| Founded | 1998 | 1997 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Major Chemicals | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.0B | 881.9M |
| IPO Year | 2011 | 2013 |
Fundamental Metrics
Financial Performance| Metric | SLI | XNCR |
|---|---|---|
| Price | $4.36 | $11.47 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 3 | 10 |
| Target Price | $5.25 | ★ $22.89 |
| AVG Volume (30 Days) | ★ 1.7M | 607.9K |
| Earning Date | 01-01-0001 | 05-22-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 65.36 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $125,576,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $6.52 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 13.65 |
| 52 Week Low | $1.08 | $6.92 |
| 52 Week High | $6.40 | $18.69 |
Technical Indicators
Market Signals| Indicator | SLI | XNCR |
|---|---|---|
| Relative Strength Index (RSI) | 46.39 | 44.64 |
| Support Level | $3.88 | $11.02 |
| Resistance Level | $4.42 | $12.73 |
| Average True Range (ATR) | 0.27 | 0.90 |
| MACD | 0.01 | 0.03 |
| Stochastic Oscillator | 31.67 | 22.58 |
Price Performance
Historical ComparisonAbout SLI Standard Lithium Ltd.
Standard Lithium Corp is engaged in the exploration and development of lithium brine properties in the United States. The company is focused on the exploration and development of the Arkansas Lithium Project, which is located in south-central Arkansas. Its other projects comprise the Lanxess Project, and Bristol Dry Lake Project.
About XNCR Xencor Inc.
Xencor Inc a clinical-stage biopharmaceutical company focused on discovering and developing engineered antibody therapeutics to treat patients with cancer and autoimmune diseases. The company uses its XmAb technology platform to create antibody product candidates. Its pipeline includes XmAb819, XmAb541, XmAb808, XmAb942, Plamotamab, and XmAb657. The group earns its revenue from collaboration agreements, product licensing agreements, and technology licensing agreements.